Fig. 1.
AICAr decreases cell viability in primary AML samples. Bone marrow samples of 16 AML patients were seeded at concentration 0.4 × 106/mL in medium supplemented with 50 ng/mL IL-3, IL-6, SCF and FLT3L and incubated with agents tested. a) The number of viable control cells in patient samples after 72 h as determined by trypan blue exclusion. b) Cells were incubated in triplicates with AICAr (0.1–0.5 mM), ATRA (1 μM), and combination of AICAr (0.1 mM) and ATRA (1 μM) in 96-well plates and MTT assay was performed after 96 h. The mean value of MTT assay is presented for every patient. Results are mean ± S.E.M, N = 16 c) Primary samples were incubated with agents tested in 12-well plates and the number of viable cells was determined after 72 h by trypan blue exclusion. Results are mean ± S.E.M, N = 16. Statistical significance was determined using one-way ANOVA and post-hoc Dunnett test